Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TURANDORELA: pre-operative nivolumab with or without relatlimab in resectable muscle-invasive bladder urothelial cancer
2023-507460-39-00Phase 3Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in transitional cell carcinoma of the bladder (TCC) and muscle-invasive bladder cancer (MIBC) comparing Nivolumab with Nivolumab + relatlimab (2 arms). Primary endpoint: Pathological complete response. Planned start Jan 2024; status: authorised.
02
Drugs
nivolumabrelatlimab
03
Conditions
transitional cell carcinoma of the bladder (TCC)muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on 2023-507460-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507460-39-00.